We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bispecific antibodies rise again.
- Authors
Garber, Ken
- Abstract
The article reports on the development of bispecific antibodies for the treatment of autoimmunity and cancer. It discusses the disadvantages of the bispecific antibody blinatumomab submitted by biopharmaceutical company Amgen Inc. to the U.S. Food and Drug Administration (FDA) for regulatory review. It also presents a table that lists the bispecific antibodies in clinical development including Ertumaxomab from pharmaceutical company Trion Pharma GmbH.
- Subjects
BISPECIFIC antibodies; THERAPEUTIC use of immunoglobulins; AUTOIMMUNITY; CANCER treatment; AMGEN Inc.; UNITED States. Food &; Drug Administration; TRION Pharma GmbH; PREVENTION
- Publication
Nature Reviews Drug Discovery, 2014, Vol 13, Issue 11, p799
- ISSN
1474-1776
- Publication type
Article
- DOI
10.1038/nrd4478